Holen Sie sich die Stockscreener-App
92.22
1.84%
1.67
Handel nachbörslich:
92.20
-0.02
-0.02%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CVS?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$90.55
Offen:
$91.155
24-Stunden-Volumen:
11.04M
Relative Volume:
1.39
Marktkapitalisierung:
$117.67B
Einnahmen:
$407.94B
Nettoeinkommen (Verlust:
$2.90B
KGV:
40.50
EPS:
2.2771
Netto-Cashflow:
$7.39B
1W Leistung:
+12.45%
1M Leistung:
+16.25%
6M Leistung:
+15.46%
1J Leistung:
+37.70%
1-Tages-Spanne:
$90.63
$92.77
1-Wochen-Bereich:
$80.40
$92.77
52-Wochen-Spanne:
$58.35
$92.77
Cvs Health Corp Stock (CVS) Company Profile
Firmenname
Cvs Health Corp
Sektor
Branche
Telefon
(401) 765-1500
Adresse
ONE CVS DR., WOONSOCKET
Compare CVS vs UNH, ELV, CI, HUM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CVS
Cvs Health Corp
|
92.22 | 115.54B | 407.94B | 2.90B | 7.39B | 2.2771 |
UNH
Unitedhealth Group Inc
|
384.44 | 345.08B | 449.71B | 12.81B | 19.67B | 13.24 |
ELV
Elevance Health Inc
|
381.75 | 82.10B | 200.42B | 5.24B | 6.45B | 23.50 |
CI
Cigna Group
|
289.07 | 76.20B | 278.13B | 6.74B | 7.66B | 23.60 |
HUM
Humana Inc
|
274.26 | 33.01B | 137.20B | 1.15B | 1.27B | 9.3439 |
Cvs Health Corp Stock (CVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-12 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2025-10-14 | Eingeleitet | Goldman | Buy |
| 2025-08-18 | Hochstufung | UBS | Neutral → Buy |
| 2025-08-14 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-02-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-02-12 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-01-30 | Hochstufung | Edward Jones | Hold → Buy |
| 2024-12-03 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-11-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-10-10 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-10-04 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-05-30 | Eingeleitet | Robert W. Baird | Neutral |
| 2024-05-07 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-05-02 | Herabstufung | UBS | Buy → Neutral |
| 2024-05-01 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-05-01 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-06 | Eingeleitet | Barclays | Equal Weight |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-22 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-19 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-09-12 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-08-18 | Herabstufung | Edward Jones | Buy → Hold |
| 2023-05-26 | Eingeleitet | Piper Sandler | Overweight |
| 2023-04-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-11-23 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-06-17 | Eingeleitet | Loop Capital | Buy |
| 2022-05-27 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2022-03-29 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-02-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-12-14 | Eingeleitet | Goldman | Buy |
| 2021-12-01 | Eingeleitet | Seaport Research Partners | Buy |
| 2021-05-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-03-17 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-01-08 | Hochstufung | Jefferies | Hold → Buy |
| 2020-09-17 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-01 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-05-14 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-09-27 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2019-09-12 | Eingeleitet | Deutsche Bank | Buy |
| 2019-06-05 | Hochstufung | Standpoint Research | Hold → Buy |
| 2019-04-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-04-18 | Eingeleitet | Guggenheim | Buy |
| 2019-04-15 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2019-04-10 | Bestätigt | BofA/Merrill | Buy |
| 2019-03-13 | Eingeleitet | Bernstein | Outperform |
| 2019-02-20 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2019-01-17 | Eingeleitet | UBS | Buy |
| 2018-12-18 | Eingeleitet | Barclays | Overweight |
| 2018-11-29 | Fortgesetzt | Goldman | Neutral |
| 2018-11-28 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-26 | Fortgesetzt | Wolfe Research | Peer Perform |
| 2018-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-02-27 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-02-13 | Bestätigt | Citigroup | Neutral |
Alle ansehen
Cvs Health Corp Aktie (CVS) Neueste Nachrichten
Insider Sell: Tilak Mandadi Sells 69,551 Shares of CVS Health Co - GuruFocus
CVS Health EVP, chief exp & tech officer Mandadi sells $6.23m in stock - Investing.com Australia
CVS Health (NYSE: CVS) EVP sells 69,551 shares at $89.58 - Stock Titan
CVS Health Corp. stock outperforms competitors on strong trading day - MarketWatch
CVS Maintained by TD Cowen -- Price Target Raised to $110 - GuruFocus
CVS Health Stock Breaks Out as Technical Indicators Turn Bright Green - Barchart.com
A Look At CVS Health (CVS) Valuation After Earnings Beat And Raised 2026 Guidance - Yahoo Finance
TD Cowen raises CVS Health stock price target to $110 on guidance - Investing.com
Mizuho raises CVS Health stock price target on margin recovery - Investing.com
Mizuho raises CVS Health stock price target on margin recovery By Investing.com - Investing.com Canada
How CVS Health pharmacists support Florida communities - The Business Journals
CVS Health: Still Cheap And Signs Of Improvement (NYSE:CVS) - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
CVS Q1 earnings preview: Health services likely to lead performance - MSN
CVS Health Q1 Earnings Call Highlights - Yahoo Finance
Jim Cramer on CVS: “I Would Argue That It’s Cheaper” - Insider Monkey
CVS Health Corp. stock (US1266501006): Earnings and dividend update in focus for US investors - AD HOC NEWS
Is CVS Health Corp (CVS) Overvalued After 3.6% Rally? GF Value S - GuruFocus
CVS Health Corp Stock (CVS) Closed Up by 3.57% on May 8: Drivers Behind the Movement - TradingKey
CVS Health Corp stock (US1266501006): Raises 2026 EPS and cash flow guidance after strong Q1 2026 re - AD HOC NEWS
Jim Cramer’s Big Prediction About CVS Health (CVS) Turned Out To Be Right - Insider Monkey
CVS Maintained by UBS -- Price Target Raised to $100 - GuruFocus
CVS Health Surprise Sparks Buzz In S&P 500 Index - Kalkine Media
CVS Sees Strong Leverage Ratio Improvement by Year-End - GuruFocus
CVS to offer primary care services after deal with Hartford HealthCare - Greenwich Time
CVS Maintains by Truist Securities -- Price Target Raised to $10 - GuruFocus
CVS Maintained by Barclays -- Price Target Raised to $101 - GuruFocus
CVS Maintained by Evercore ISI Group -- Price Target Raised to $105 - GuruFocus
Earnings call transcript: CVS Health beats Q1 2026 forecasts, stock steady - Investing.com Australia
CVS Health Earnings Call Highlights Growth And Risks - TipRanks
CVS Health Q1 2026 slides: earnings beat drives guidance raise - Investing.com
CVS Health (NYSE: CVS) reports 33 holdings totaling $212.3M in Form 13F - Stock Titan
CVS stores now accepting WIC for infant formula across Rhode Island - AOL.com
These Analysts Increase Their Forecasts On CVS Health After Strong Q1 Results - Benzinga
CVS Health Q1 FY26 earnings call | $CVS | 🔴 watch live - MSN
Aetna Better Health of Missouri Commits $175K to Community Health - CVS Health
MinuteClinic® and Hartford HealthCare expand primary care access across Connecticut - CVS Health
Truist raises CVS Health stock price target to $102 on margin gains - Investing.com
CVS Health Q1 2026 slides: strong results drive raised guidance By Investing.com - Investing.com Australia
CVS Health raises 2026 forecast after improving medical cost controls By Reuters - Investing.com
BofA raises CVS Health stock price target to $100 on margin outlook - Investing.com
CVS Health raises FY26 adjusted EPS view to $7.30-$7.50 from $7.00-$7.20 - TipRanks
CVS Health (CVS) Shares Skyrocket, What You Need To Know - Barchart.com
Why CVS Stock Skyrocketed on Wednesday - Yahoo Finance
CVS Exceeds Q1 Expectations on Revenue, Earnings Growth - HomePage News
CVS beats Wall Street, but warns of headwinds - The Business Journals
CVS boosts outlook for 2026 after Aetna profits increase - The Boston Globe
CVS Health shares jump on earnings beat and raised guidance - Investing.com
CVS Earnings: Ongoing Margin Improvement at Medical Insurer Boosts Shares - Morningstar
CVS execs say company on track to meet MA margin goals by 2028 - Fierce Healthcare
CVS earnings, revenue top Street amid improvements in Aetna insurance business - Chain Store Age
Finanzdaten der Cvs Health Corp-Aktie (CVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.97%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):